HRP20230946T1 - Konjugati montelukasta i peptida - Google Patents
Konjugati montelukasta i peptida Download PDFInfo
- Publication number
- HRP20230946T1 HRP20230946T1 HRP20230946TT HRP20230946T HRP20230946T1 HR P20230946 T1 HRP20230946 T1 HR P20230946T1 HR P20230946T T HRP20230946T T HR P20230946TT HR P20230946 T HRP20230946 T HR P20230946T HR P20230946 T1 HRP20230946 T1 HR P20230946T1
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- hyp
- lys
- tyr
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 13
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title claims 2
- 229960005127 montelukast Drugs 0.000 title claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 241000700605 Viruses Species 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 206010061218 Inflammation Diseases 0.000 claims 9
- 230000004054 inflammatory process Effects 0.000 claims 9
- 208000027866 inflammatory disease Diseases 0.000 claims 7
- 206010023332 keratitis Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 claims 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 4
- 229960004502 levodopa Drugs 0.000 claims 4
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 101150096038 PTH1R gene Proteins 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 206010006451 bronchitis Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- LLGQICNFACCGPR-LDXVMNHOSA-N 2-[1-[[(1r)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-(2-prop-1-en-2-ylphenyl)propyl]sulfanylmethyl]cyclopropyl]acetic acid Chemical compound CC(=C)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 LLGQICNFACCGPR-LDXVMNHOSA-N 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 241000711573 Coronaviridae Species 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 241000709661 Enterovirus Species 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 208000014617 hemorrhoid Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 2
- 208000022218 streptococcal pneumonia Diseases 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 206010069408 Acanthamoeba keratitis Diseases 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000035939 Alveolitis allergic Diseases 0.000 claims 1
- 206010001986 Amoebic dysentery Diseases 0.000 claims 1
- 201000002909 Aspergillosis Diseases 0.000 claims 1
- 208000036641 Aspergillus infections Diseases 0.000 claims 1
- 208000004429 Bacillary Dysentery Diseases 0.000 claims 1
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241000702669 Coltivirus Species 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 claims 1
- 201000007336 Cryptococcosis Diseases 0.000 claims 1
- 241000221204 Cryptococcus neoformans Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 206010014568 Empyema Diseases 0.000 claims 1
- 208000004145 Endometritis Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 208000014260 Fungal keratitis Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 208000037262 Hepatitis delta Diseases 0.000 claims 1
- 241000724709 Hepatitis delta virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241001479210 Human astrovirus Species 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000702617 Human parvovirus B19 Species 0.000 claims 1
- 241000829111 Human polyomavirus 1 Species 0.000 claims 1
- 241000712431 Influenza A virus Species 0.000 claims 1
- 241000713196 Influenza B virus Species 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 241000701460 JC polyomavirus Species 0.000 claims 1
- 206010023335 Keratitis interstitial Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 241000712902 Lassa mammarenavirus Species 0.000 claims 1
- 241001115401 Marburgvirus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 claims 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029443 Nocardia Infections Diseases 0.000 claims 1
- 206010029444 Nocardiosis Diseases 0.000 claims 1
- 241001263478 Norovirus Species 0.000 claims 1
- 241000714209 Norwalk virus Species 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 241000243985 Onchocerca volvulus Species 0.000 claims 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 1
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 241000702259 Orbivirus Species 0.000 claims 1
- 241000150452 Orthohantavirus Species 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010034944 Photokeratitis Diseases 0.000 claims 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 claims 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 claims 1
- 206010035734 Pneumonia staphylococcal Diseases 0.000 claims 1
- 206010035737 Pneumonia viral Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037422 Pulmonary mycosis Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010037508 Punctate keratitis Diseases 0.000 claims 1
- 206010038664 Respiratory alkalosis Diseases 0.000 claims 1
- 241000711931 Rhabdoviridae Species 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 241000606701 Rickettsia Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 206010058339 Splenitis Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 206010044302 Tracheitis Diseases 0.000 claims 1
- 206010044314 Tracheobronchitis Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 206010061418 Zygomycosis Diseases 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 230000007950 acidosis Effects 0.000 claims 1
- 208000026545 acidosis disease Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000007691 actinomycosis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000009285 allergic inflammation Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 208000034526 bruise Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 208000020670 canker sore Diseases 0.000 claims 1
- 206010008323 cervicitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 208000010227 enterocolitis Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 201000009819 exposure keratitis Diseases 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000017762 fibroma of lung Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000037799 influenza C Diseases 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000006904 interstitial keratitis Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007524 mucormycosis Diseases 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 206010069732 neurotrophic keratopathy Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000005111 ocular hyperemia Diseases 0.000 claims 1
- 208000002042 onchocerciasis Diseases 0.000 claims 1
- 208000005963 oophoritis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 201000005113 shigellosis Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 208000004048 staphylococcal pneumonia Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 208000009421 viral pneumonia Diseases 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Spoj koji sadrži peptid koji sadrži peptidnu komponentu koja sadrži ili se sastoji od:
(a) aminokiselinske sekvence:
X-Pro-Y-Z (SEQ ID No: 5),
gdje:
X predstavlja lanac od 1 do 2 aminokiselinska ostatka od kojih je svaki nezavisno izabran iz grupe koju čine Ala i Lys;
Y je izabran iz grupe koju čine Ser i pSer; i
Z predstavlja lanac od 1 do 7 aminokiselinskih ostataka od kojih je svaki nezavisno izabran iz grupe koju čine Tyr, pTyr, 3Hyp ili 4Hyp, Thr, pThr, DOPA i Lys;
(b) aminokiselinske sekvence:
G1-Lys-Pro-G2-T-Hyp-G3-Lys (SEQ ID No: 7),
gdje
G1 je odsutan ili predstavlja Ala;
G2 je izabran iz grupe koju čine Ser i pSer;
T je izabran iz grupe koju čine DOPA, Tyr i pTyr;
Hyp je izabran iz grupe koju čine 3Hyp i 4Hyp; i
G3 predstavlja lanac od 1 do 3, ili 1 do 4, aminokiselinskih ostataka od kojih je svaki nezavisno izabran iz grupe koju čine Tyr, pTyr, 3Hyp, 4Hyp, Thr, pThr i DOPA;
(c) aminokiselinske sekvence:
Lys-Pro-G2-T-Hyp-G3-Lys (SEQ ID No: 8),
gdje G2, T, Hyp i G3 su kao što je gore definirano; ili
(d) aminokiselinske sekvence:
Ala-Lys-Pro-G2-T-Hyp-Hyp-Thr-G4-Lys (SEQ ID No: 9),
gdje G4 je izabran iz grupe koju čine Tyr, pTyr, 3Hyp, 4Hyp, Thr, pThr iDOPA, i G2,
T, i Hyp su kako je gore opisano; i
bar jedan od Lys ostataka, i/ili, su bili prisutni, Ala ostatak, peptidne komponente je kovalentno vezan za jedan ili više spojeva formule I,
[image]
gdje:
R1 je izabran iz grupe koju čine -C(CH3)2OH, -COCH3, -C(CH3)=CH2 i -C(CH3)2H; i n je 0, 1 ili 2,
kao i regioizomeri, stereoizomeri i farmaceutski-ili kozmetički prihvatljive soli spomenutog jedinjenja koje sadrži peptid.
2. Spoj koji sadrži peptid prema zahtjevu 1, gdje
G1 predstavlja Ala;
G2 predstavlja Ser;
T predstavlja Tyr; i/ili.
G3 ili G4 (po potrebi) predstavlja Tyr iliDOPA.
3. Spoji koji sadrži peptid prema zahtjevu 1 ili zahtjevu 2, gdje peptidna komponenta sadrži ili se sastoji od aminokiselinske sekvence:
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 4);
Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 11);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 12);
Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 13);
Lys-Pro-Ser-Tyr-Hyp-DOPA-Lys (SEQ ID No: 14);
Lys-Pro-Ser-pTyr-Hyp-DOPA-Lys (SEQ ID No: 15);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 18);
Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 19);
Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 20);
Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 21);
Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 22),
Ala-Lys-Pro-pSer-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 23);
Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 24); i
Ala-Lys-Pro-pSer-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 25).
4. Spoj koji sadrži peptid prema bilo kojem od prethodnih zahtjeva, gdje jedan ili više spojeva formule I je/su montelukast, montelukast stiren, ili hidrogenizovani montelukast stiren.
5. Spoj koji sadrži peptid kako je definirano u bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski ili kozmetički prihvatljiva sol, za upotrebu kao farmaceutsko sredstvo.
6. Farmaceutska formulacija koja sadrži spoj kako je definirano u bilo kojem od zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva- ili kozmetički prihvatljiva sol, adjuvans, razblaživač ili nosač.
7. Spoj koji sadrži peptid kako je definirano u bilo kojem od zahtjeva 1 do 4, njegova farmaceutski prihvatljiva- ili kozmetički prihvatljiva sol, ili formulacija kako je definirano u zahtjevu 6, za upotrebu u liječenju inflamacije, inflamatornog poremećaja, i/ili poremećaja okarakteriziranog upalom, ili za upotrebu u liječenju idiopatske pulmonarne fibroze.
8. Spoj, ili formulacija, za upotrebu prema zahtjevu 7, gdje:
(a) upalni poremećaj obuhvaća upalu jednog ili više mekih tkiva, zglobova, živaca, vaskularnog sistema, jednog ili više unutrašnjih organa, jedne ili više mukoznih površina ili kože;
(b) upalni poremećaj obuhvaća upalu jedne ili više mukoznih površina i izabran je grupe koju čine oralni mukozitis, aftozni čir, upala srednjeg uha, laringitis, traheitis, ezofagitis, gastritis, enteritis i enterokolitis, bacilarna dizenterija, kronična amebna dizenterija, šistosomijaza, nespecifični ulcerozni kolitis i regionalni enteritis, cervicitis i endocervicitis, endometritis, inflamacija izazvana inhalacijskom povredom i slično, kao i upala sluzokože povezane s rakom, i infekcije;
(c) upalni poremećaj obuhvaća upalu srca, želudca, crijeva, pluća, jetre, slezene, bubrega, pankreasa, mjehura, jajnika ili prostate, perikarditis, miokarditis, endokarditis, upalu pluća, hepatitis, splenitis, nefritis pankreatitis, cistitis, ooforitis, prostatitis ili čir na želudcu;
(d) upalni poremećaj je izabran između psorijaze, akni, ekcema, dermatitisa, seboreičnog dermatitisa, rinitisa, konjunktivitisa, hemoroida, hronične obstruktivne bolesti pluća, uključujući enfizem ili kronični bronhitis, i inflamatornu bolest crijeva;
(e) upalni poremećaj obuhvaća upalu oka i okolnog područja, konjuktivitis, keratitis ili optički neuritis; i/ili
(f) poremećaj karakteriziran upalom je, ili dovodi do, rane ili opekotine.
9. Spoj, ili formulacija, za upotrebu prema zahtjevu 8, gdje:
(a) upalni poremećaj je astma, alergijski rinitis, alergijski/atopijski dermatitis ili seboreični dermatitis;
(b) inflamatrona bolest crijeva je ulcerozni kolitis ili Kronova bolest;
(c) upalni poremećaj oka je izabran između alergijskog konjuktivitisa, akutnog epitelnog keratitisa, numularnog keratitisa, intersticijalnog keratitisa, disciformnog keratitisa, neurotrofičnog keratitisa, keratitisa mukoznog plaka, herpes simpleks keratitisa, herpes zoster keratitisa, bakterijskog keratitisa, gljivičnog keratitisa akantamebnog keratitisa, onhocerkijaznog keratitisa, površinskog punktatnog keratitisa, ulceroznog keratitisa, ekspozicijskog keratitisa fotokeratitisa i akutnog crvenog oka uslijed kontaktnih sočiva;
(d) rana obuhvaća abraziju, ogrebotinu, rez, razderotinu, ubod kože, avulziju, modricu, ožiljak ili plikove; i/ili
(e) poremećaj koji dovodi do rane su hemoroidi ili ulcerozni kolitis
10. Spoj koji sadrži peptid kako je definirano prema bilo kojem od zahtjeva 1 do 4, ili njegova farmaceutski ili komercijalno prihvatljiva sol, ili formulacija kako je definirano prema zahtjevu 6, za upotrebu u liječenju stanja pluća i/ili fibrotičkog stanja, izabranih između fibroze pluća, fibroze bubrega, fibroze jetre, silikoze, akutnog bronhitisa, kroničnog bronhitisa, traheobronhitisa, bronhijalne astme, asmatičnih statusa, bronhiektazije, infekcije gornjih disajnih puteva, uključujući prehladu i gripu), alergijskog zapaljenja dišnih puteva, bakterijske upale pluća, virusne upale pluća, mikoplazma upale pluća, rikecije, upale pluća izazvane zračenjem, upale pluća izazvane pneumokokama, stafilokokama , upale pluća izazvane streptokokama, upale pluća izazvane gram-negativnim bacilom, plućne kandidijaze, aspergiloze, mukormikoze, histoplazmoze, aktinomikoze, nokardioze, plućne mikoze, kriptokokoze, apscesa pluća, anafilaktičke upale pluća, Leoferovog sindroma, ekstrinzičnog alergijskog alveolitisa, plućne eozionfilije, eozinofiloze, opstruktivnog plućnog emfizema, pulmonarnog edema, plućne tuberkuloze, respiratorne alkaloze (acidoze), akutne povrede pluća, intersticijalne bolesti pluća, empijema, fibroma pluća i plućnog srca.
11. Spoj, ili formulacija, za upotrebu kao u zahtjevu 10, gdje je stanje izabrano između idiopatske plućne fibroze ili akutne povrede pluća.
12. Spoj koji sadrži peptid kako je definirano u bilo kojem od zahtjeva 1 do 4, ili njegova farmaceutska ili kozmetički prihvatljiva sol, ili formulacija kako je definirano u zahtjevu 6, za upotrebu u liječenju virusne infekcije, izazavane s jednim ili više virusa izabranih između adenovirusa, humanog papilomavirusa, BK virusa, JC virusa, herpes simpleksa, virusa tipa 1, herpes simpleksa, virusa tipa 2, virusa varičela-zostera, Epštajn-Barovog virusa, humanog citomegalovirusa, humanog virusa herpesa, tipa 8, velikih boginja, virusa hepatitisa B , parvovirusa B19, humanog astrovirusa, norovirusa, Norvalk virusa, koksaki virusa, virusa hepatitisa A , poliovirusa, rinovirusa, korona virusa, virusa hepatitisa C , virusa žute groznice, denga virusa, virusa Zapadnog Nila, virusa encefalitisa iz krpelja, virusa humane imunodeficijence, virusa rubeole, Lasa virusa, hanta virusa, virusa Krimske-Kongo hemoragijske groznice, Hantan virus, Ebola virusa, Marburg virusa, Ravn virusa, virusa gripa, virusa malih boginja, virusa zauški, parainfluenza virusa, respiratornog sincitijalnog virusa, rhabdoviridae, virusa hepatitisa E , rotavirusa, orbivirusa, coltivirusa, Bana virusa i virusa hepatitisa D .
13. Spoj, ili formulacija, za upotrebu prema zahtjevu 12, gdje je virus izabran između adenovirusa, humanog papilomavirusa, herpes simpleksa, virusa tipa 1 , herpes simpleksa, virusa tipa 2, rhinovirusa, koronavirusa, virusa gripa A, virusa gripa B ili virusa gripa C, parainfluenza virusa i respiratornog sincitijalnog virusa.
14. Spoj, ili formulacija, za upotrebu prema zahtjevu 13, gdje virus izaziva infekciju dišnih puteva.
15. Spoj, ili formulacija, za upotrebu prema bilo kojem od zahtjeva 5 ili 7 do 14 (po potrebi), gdje jedinjenja ili njihova sol je davano u obliku lokalne formulacije za liječenje relevantnog stanja pomoćnu direktnog lokalnog davanja na kožu, ili mukoznu površinu.
16. Spoj, ili formulacija, za upotrebu prema bilo kojem od zahtjeva 5 ili 7 do 15 (po potrebi), gdje su spojevi davani oralno, intravenski, intraarterijski, intravaskularno, perivaskularno, intramuskularno, kutanozno, subkutanozno, transmukozno, sublingvalno, bukalno, rektalno, intravagnalno, transdermalno, nazalno, pulmonarno, trahealno, bronhijalno, intraperitonealno ili anorektalno .
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018105703 | 2018-09-14 | ||
| CN2018119072 | 2018-12-04 | ||
| EP19856467.6A EP3678705B1 (en) | 2018-09-14 | 2019-09-14 | Conjugates of montelukast and peptides |
| PCT/CN2019/105832 WO2020052677A1 (en) | 2018-09-14 | 2019-09-14 | New conjugates of montelukast and peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230946T1 true HRP20230946T1 (hr) | 2023-11-24 |
Family
ID=69777394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230946TT HRP20230946T1 (hr) | 2018-09-14 | 2019-09-14 | Konjugati montelukasta i peptida |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11680082B2 (hr) |
| EP (2) | EP3678705B1 (hr) |
| JP (1) | JP2022500437A (hr) |
| KR (1) | KR20210061372A (hr) |
| CN (2) | CN111601618A (hr) |
| AU (1) | AU2019338582A1 (hr) |
| BR (1) | BR112021004823A2 (hr) |
| CA (1) | CA3112420A1 (hr) |
| DK (1) | DK3678705T3 (hr) |
| ES (1) | ES2956509T3 (hr) |
| FI (1) | FI3678705T3 (hr) |
| HR (1) | HRP20230946T1 (hr) |
| HU (1) | HUE062848T2 (hr) |
| IL (1) | IL281426A (hr) |
| LT (1) | LT3678705T (hr) |
| MX (1) | MX2021002657A (hr) |
| PL (1) | PL3678705T3 (hr) |
| PT (1) | PT3678705T (hr) |
| RS (1) | RS64436B1 (hr) |
| SG (1) | SG11202102119RA (hr) |
| SI (1) | SI3678705T1 (hr) |
| TW (1) | TW202023623A (hr) |
| WO (1) | WO2020052677A1 (hr) |
| ZA (1) | ZA202101398B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3068818A1 (en) * | 2017-07-05 | 2019-01-10 | Jiangyin Mucocare Pharmaceutical Co., Ltd | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
| TW202120523A (zh) * | 2019-09-14 | 2021-06-01 | 大陸商江陰貝瑞森製藥有限公司 | 新肽 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| AU2021254262A1 (en) * | 2020-04-10 | 2022-11-03 | University Of Georgia Research Foundation, Inc. | Methods for treatment of coronavirus infections |
| KR102596264B1 (ko) * | 2020-11-30 | 2023-11-01 | 주식회사 바이오빛 | 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물 |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| WO2022193185A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New conjugates |
| WO2023225107A1 (en) * | 2022-05-17 | 2023-11-23 | Emory University | Diroximel fumarate, inhalation administration methods, pharmaceutical uses and compositions |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| WO2003020200A2 (en) | 2000-11-16 | 2003-03-13 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound and methods of making and using same |
| RS20050007A (en) | 2002-07-08 | 2007-09-21 | Glaxo Smith Kline Istraživački Centar Zagreb D.O.O., | Novel nonsteroidal anti- inflammatory substances, compositions and methods for their use |
| US20050107612A1 (en) | 2002-12-30 | 2005-05-19 | Dr. Reddy's Laboratories Limited | Process for preparation of montelukast and its salts |
| EP1613273B1 (en) * | 2003-04-11 | 2012-06-13 | MedImmune, LLC | Recombinant il-9 antibodies and uses thereof |
| EP1617805A4 (en) * | 2003-04-11 | 2012-07-04 | Medimmune Llc | METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| WO2005046575A2 (en) | 2003-07-29 | 2005-05-26 | Signature R & D Holdings, Lcc | Amino acid prodrugs |
| KR20070083811A (ko) * | 2004-10-27 | 2007-08-24 | 글락소스미쓰클라인 이스트라지바치키 센타 자그레브 디.오.오. | 항-염증 활성을 가진 접합체 |
| CN102068432A (zh) | 2011-01-11 | 2011-05-25 | 李仲昆 | 一种由他定类和白三烯拮抗剂组成的外用复方组合物 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| AU2013262320B2 (en) | 2012-05-16 | 2018-02-22 | Techfields Pharma Co., Ltd. | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
| CA2992109C (en) | 2015-07-20 | 2022-10-11 | Min Gao | Map product and use thereof for inhibiting skin inflammation |
| CA3064145A1 (en) | 2017-05-24 | 2018-11-29 | Transfert Plus, S.E.C. | Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases |
| CA3068818A1 (en) * | 2017-07-05 | 2019-01-10 | Jiangyin Mucocare Pharmaceutical Co., Ltd | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
| MA52988A (fr) | 2017-07-05 | 2021-05-05 | Jiangyin Usun Pharmaceutical Co Ltd | Utilisation anti-inflammatoire du peptide |
-
2019
- 2019-09-14 HU HUE19856467A patent/HUE062848T2/hu unknown
- 2019-09-14 US US16/645,355 patent/US11680082B2/en active Active
- 2019-09-14 CA CA3112420A patent/CA3112420A1/en active Pending
- 2019-09-14 CN CN201980004399.1A patent/CN111601618A/zh active Pending
- 2019-09-14 CN CN202310240501.6A patent/CN116785447A/zh active Pending
- 2019-09-14 AU AU2019338582A patent/AU2019338582A1/en active Pending
- 2019-09-14 SI SI201930561T patent/SI3678705T1/sl unknown
- 2019-09-14 PL PL19856467.6T patent/PL3678705T3/pl unknown
- 2019-09-14 MX MX2021002657A patent/MX2021002657A/es unknown
- 2019-09-14 WO PCT/CN2019/105832 patent/WO2020052677A1/en active Application Filing
- 2019-09-14 KR KR1020217010829A patent/KR20210061372A/ko unknown
- 2019-09-14 DK DK19856467.6T patent/DK3678705T3/da active
- 2019-09-14 EP EP19856467.6A patent/EP3678705B1/en active Active
- 2019-09-14 FI FIEP19856467.6T patent/FI3678705T3/fi active
- 2019-09-14 RS RS20230654A patent/RS64436B1/sr unknown
- 2019-09-14 BR BR112021004823-5A patent/BR112021004823A2/pt unknown
- 2019-09-14 PT PT198564676T patent/PT3678705T/pt unknown
- 2019-09-14 LT LTEPPCT/CN2019/105832T patent/LT3678705T/lt unknown
- 2019-09-14 SG SG11202102119RA patent/SG11202102119RA/en unknown
- 2019-09-14 EP EP23176152.9A patent/EP4253404A3/en active Pending
- 2019-09-14 HR HRP20230946TT patent/HRP20230946T1/hr unknown
- 2019-09-14 ES ES19856467T patent/ES2956509T3/es active Active
- 2019-09-14 JP JP2021514112A patent/JP2022500437A/ja active Pending
- 2019-09-16 TW TW108133243A patent/TW202023623A/zh unknown
-
2021
- 2021-03-01 ZA ZA2021/01398A patent/ZA202101398B/en unknown
- 2021-03-11 IL IL281426A patent/IL281426A/en unknown
-
2023
- 2023-05-12 US US18/316,496 patent/US20230348536A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111601618A (zh) | 2020-08-28 |
| KR20210061372A (ko) | 2021-05-27 |
| CN116785447A (zh) | 2023-09-22 |
| DK3678705T3 (en) | 2023-06-26 |
| US20210309696A1 (en) | 2021-10-07 |
| SG11202102119RA (en) | 2021-04-29 |
| US20230348536A1 (en) | 2023-11-02 |
| ES2956509T3 (es) | 2023-12-22 |
| TW202023623A (zh) | 2020-07-01 |
| EP3678705A1 (en) | 2020-07-15 |
| FI3678705T3 (fi) | 2023-07-04 |
| PL3678705T3 (pl) | 2023-10-09 |
| LT3678705T (lt) | 2023-08-10 |
| PT3678705T (pt) | 2023-07-19 |
| US11680082B2 (en) | 2023-06-20 |
| JP2022500437A (ja) | 2022-01-04 |
| IL281426A (en) | 2021-04-29 |
| EP4253404A2 (en) | 2023-10-04 |
| EP3678705B1 (en) | 2023-05-31 |
| MX2021002657A (es) | 2021-07-21 |
| EP4253404A3 (en) | 2023-12-13 |
| EP3678705A4 (en) | 2021-06-09 |
| RS64436B1 (sr) | 2023-09-29 |
| BR112021004823A2 (pt) | 2021-06-08 |
| ZA202101398B (en) | 2022-09-28 |
| HUE062848T2 (hu) | 2023-12-28 |
| AU2019338582A1 (en) | 2020-11-19 |
| CA3112420A1 (en) | 2020-03-19 |
| WO2020052677A1 (en) | 2020-03-19 |
| SI3678705T1 (sl) | 2023-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230946T1 (hr) | Konjugati montelukasta i peptida | |
| JP6694886B2 (ja) | ４，５−ジヒドロ−６Ｈ−チエノ［３，２−ｄ］ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス（ＲＳＶ）感染を治療するためのその使用 | |
| CN103687488B (zh) | 化学和代谢稳定的具有钠通道阻滞剂活性的二肽 | |
| JP5611844B2 (ja) | 多環芳香族ナトリウムチャネル遮断薬 | |
| JP2014114269A (ja) | 定量吸入器を用いたトレプロスチニル投与 | |
| RU2018138195A (ru) | Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида | |
| KR20090065508A (ko) | 나트륨 채널 차단제와 삼투질 처리에 의한 점막 수화와 점막 세척 촉진 방법 | |
| BR112016003481A2 (pt) | Agentes mucolíticos de ditiol | |
| ES2938085T3 (es) | Compuestos de amida, métodos de preparación y uso de los mismos como agentes para el tratamiento y prevención de enfermedades causadas por virus que contienen ARN y/o ADN y enfermedades concomitantes | |
| JPWO2020052677A5 (hr) | ||
| MX2010008744A (es) | Derivados de pteridina para tratar enfermedad respiratoria. | |
| JP2018520986A5 (hr) | ||
| ES2927948T3 (es) | Peptidomimético de horquilla beta con actividad inhibidora de elastasa y formas de dosificación en aerosol del mismo | |
| Diehl et al. | Bronchiolitis obliterans organizing pneumonia associated with chlamydial infection | |
| CN110753688A (zh) | 用于治疗呼吸系统疾病的化合物 | |
| JP2023514074A (ja) | 炎症性肺疾患の吸入治療における５－アミノ－２，３－ジヒドロ－１，４－フタラジンジオンの使用 | |
| PT2285393E (pt) | Composições para o tratamento de distúrbios do tracto respiratório superior e síndromes gripais | |
| RU2021105972A (ru) | Новые конъюгаты монтелукаста и пептидов | |
| KR20020072576A (ko) | 디아미노트리플루오로메틸피리딘의 유도체를 함유하는 폐부전 치료제 또는 예방제 | |
| US9795625B2 (en) | Uridine and uridine analogues for treatment of specific lung diseases, namely COPD and pulmonary fibrosis | |
| JP5311825B2 (ja) | ２−イミダゾリン構造を有するα−交感神経興奮薬の新規な使用 | |
| EA044475B1 (ru) | Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний | |
| CN117529329A (zh) | 治疗呼吸窘迫的组合物和方法 | |
| WO2023169557A1 (zh) | 一种次黄碱衍化合物在制备治疗肺纤维化药物中的应用 | |
| EA038170B1 (ru) | Составы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний |